N/A
Completed N=11,296
A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Source: ClinicalTrials.gov NCT03979807 ↗
Enrolled (actual)
11,296
Serious AEs
—
Results posted
Jul 2020
Primary outcomePrimary: Rate of Discontinuation of Index Treatment (Olodaterol/Tiotropium Bromide or Umeclidinium/Vilanterol) — 1826.00; 1647.03 Events per 1000 person-years
Summary
To compare the persistence in using two different medications from the same drug class (LAMA/LABA FDC) which are delivered through different devices, a dry-powder inhalers (DPI) and Soft Mist Inhalers (SMI).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rate of Discontinuation of Index Treatment (Olodaterol/Tiotropium Bromide or Umeclidinium/Vilanterol) |
1826.00; 1647.03 | — |
Eligibility Criteria
Inclusion Criteria
-
Exclusion Criteria
- Aged <40 years
- Enrolment with medical and pharmacy coverage prior to the cohort entry < 180 days
- Never had COPD diagnosis on the cohort entry date or prior to cohort entry
- A record for dispensed Olodaterol/Tiotropium Bromide delivered with Respimat inhalator or Umeclidinium/Vilanterol delivered with the Ellipta Inhaler during the 180-day baseline prior to cohort entry
- Diagnosis of asthma any time prior to cohort entry
- Diagnosis of lung cancer any time prior to cohort entry
- Diagnosis of lung transplant any time prior to cohort entry
Data sourced from ClinicalTrials.gov (NCT03979807). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.